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Abstract
Purpose—The impact of pharmacist-assisted management (PAM) of pharmacotherapy for 
patients with human immunodeficiency virus (HIV) infection was investigated.
Methods—A retrospective cohort analysis was conducted to evaluate antiretroviral therapy 
(ART) outcomes in treatment-naive patients initiated on ART at an HIV clinic. Eligible patients 
enrolled in the clinic during the period 1999–2013 were classified into two groups: those referred 
to a clinic-based HIV pharmacist for initiation of ART (the PAM group) and those managed by a 
primary care provider (the control group). The primary study objective was the median time to 
viral suppression; secondary objectives included the durability of response to the first ART 
regimen. Relative hazards for the events of interest were estimated using a marginal structural Cox 
proportional hazards model and Kaplan–Meier curves, with inverse probability weights used to 
control for selection and confounding bias.
Results—Patients referred for PAM services (n = 819) typically had higher baseline viral loads 
and lower CD4+ cell counts than those in the control group (n = 436). The likelihood of viral 
suppression during the first two years after ART initiation was significantly higher in the PAM 
group versus the control group (hazard ratio, 1.37; 95% confidence interval, 1.18–1.59; p < 
0.0001). The median durability of the first ART regimen was 100 months in the PAM group versus 
44 months in the control group (p > 0.05).
Conclusion—In treatment-naive patients, suppression of HIV viral load occurred earlier when 
pharmacists assisted with initiating ART than when ART was initiated without that assistance.
The goals of treating patients with human immunodeficiency virus (HIV) infection are to 
reduce HIV-related morbidity and mortality, restore and preserve immunologic function, 
achieve maximal and durable suppression of the plasma HIV viral load, and prevent HIV 
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transmission.1 Currently, durable viral suppression requires strict adherence to lifelong 
antiretroviral therapy (ART), which consists of at least three active antiretroviral agents. 
Consistent adherence to ART is a predictor of viral suppression; other predictors include a 
more potent ART regimen, a lower baseline plasma viral load, a higher baseline CD4+ cell 
count, and a rapid reduction in the viral load in response to treatment.2-5
Several studies have examined the impact of pharmacists’ interventions on the treatment of 
HIV-infected patients, with most focusing on improving adherence in nonadherent patients.6 
A recent systematic review of the impact of HIV clinical pharmacists on HIV treatment 
outcomes found that, in the majority of studies, involvement by an HIV pharmacist was 
significantly associated with improvements in ART adherence and higher rates of viral load 
suppression.6
We conducted a study to further investigate the impact of pharmacists’ interventions in this 
area, specifically with regard to initiating ART in treatment-naive HIV-infected patients at a 
large academic, multidisciplinary clinic where clinical pharmacists function as part of a 
collaborative practice protocol. Our primary objective was to compare times to viral 
suppression after initiation of ART in two groups of treatment-naive patients: those receiving 
pharmacist-assisted management (PAM) services (the intervention group) and those not 
receiving PAM services (the control group). Secondary objectives were to compare the 
median times to the first regimen change in the two groups and to describe changes in 
prescribing patterns and utilization of PAM services over time.
Methods
Study setting and model of care
Our investigation took place within an adult HIV primary care clinic located in southern 
California that currently serves approximately 3000 patients. The clinic has three dedicated 
pharmacists who operate an antiretroviral management clinic (established in 1987). Each 
pharmacist has specialized training and credentials (conferred by the American Academy of 
HIV Medicine) in the management of HIV pharmaco-therapy. The pharmacists maintain 
their own patient schedule and are able to provide a variety of patient care services as part of 
a physician–pharmacist collaborative practice protocol. Patients are referred by their primary 
care provider (PCP) to the pharmacists for any of several interventions or issues, including 
initiation and change of ART, management of drug-related adverse effects, medication 
adherence problems, suspected drug resistance, and difficulties with medication coverage or 
acquisition. If a patient is not referred to a pharmacist, ART is managed by the primary HIV 
clinician (a physician, nurse practitioner, or physician assistant). The pharmacists are able to 
order laboratory tests to monitor the safety and effectiveness of ART initiation and 
modification and order medications to help manage common ART adverse effects, such as 
nausea and diarrhea, under the collaborative practice protocol. Patients continue to receive 
follow-up care from pharmacists until the issue for which they were originally referred is 
resolved, at which time they are discharged back to their PCP. Additionally, since the 
pharmacists are physically located within the clinic, they are available as a drug therapy 
resource for the clinic staff at any time. The pharmacists also assess the appropriateness of 
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resistance testing, coordinate the evaluation and implementation of new ART regimens in 
patients with viral failure, and manage the resistance database.
Study design
This study was a retrospective, observational cohort study of treatment-naive HIV-positive 
patients who were initiated on ART between January 1999 and March 2013. Eligible 
patients were identified using the clinic's computerized databases. Data were extracted from 
an electronic health record (EHR) system. The following variables were ascertained: date of 
first pharmacist intervention, date of prescribing of first ART regimen, initial ART regimen 
prescribed, baseline HIV plasma viral load and CD4+ lymphocyte count, date of first 
undetectable viral load (i.e., ≤400 HIV RNA copies/mm3), last observed viral load, 
concurrent disease states (e.g., hepatitis B or C), type of PCP (physician or midlevel 
practitioner) at baseline (i.e., prior to initiation of ART), HIV transmission risk factors, and 
demographic characteristics.
Study participants
Patients included in the study were at least 18 years of age. Eligible patients had confirmed 
HIV infection, were treatment naive at study entry, and were initiated on ART at the study 
clinic. Patients were excluded if the pretreatment viral load was not documented or was 
undetectable or if no post-treatment viral load was documented. Patients initiated on ART 
while pregnant were also excluded from the study. The study was approved by the 
University of California San Diego human research protection program.
Study outcomes
The primary endpoint of the study was the time from initiation of the first antiretroviral 
regimen to an undetectable HIV plasma viral load. Secondary endpoints were the time to the 
first regimen discontinuation or change, prescribing patterns over time by drug class, and the 
proportion of patients referred for PAM by calendar year.
Statistical analyses
Marginal structural Cox proportional hazards models were used to estimate the time to the 
first undetectable viral load and the time to the first regimen discontinuation or change. 
Patients were followed from the date of ART initiation for 24 months or until their first 
measured undetectable viral load (the primary outcome) or their first ART regimen switch (a 
secondary outcome). Patient data were censored if the patient was lost to follow-up, defined 
as 12 months without a viral load measurement. We assigned study observation weights to 
control for three potential sources of confounding and selection bias: (1) prognostic 
imbalances in baseline characteristics (controlled for with treatment weights), (2) differential 
study dropout (controlled for with censoring weights), and (3) differential frequency of viral 
load monitoring (controlled for with viral monitoring weights). To control for potential 
confounding of the intervention–outcome relationship, we defined treatment weights that 
were the inverse probability of treatment conditional on baseline viral load, baseline CD4+ 
cell count, baseline hepatitis B and C infection status, age at ART initiation, race, 
transmission group, and time period of ART initiation (1999–2001, 2002–04, 2005–08, or 
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2009–12).7,8 Continuous variables were modeled flexibly with restricted quadratic splines.9 
We included patients who did not have a measured baseline hepatitis B and C infection 
status and assumed that absence of this information was taken into account for treatment and 
monitoring decisions by the physicians as if it were simply another patient characteristic. To 
control for possible nondifferential censoring, we further defined censoring weights that 
were the cumulative inverse probability of not being censored conditional on baseline viral 
load, baseline CD4+ cell count, age at ART initiation, race, transmission group, and time 
period of ART initiation, as well as treatment group and the number of months since 
treatment initiation, modeled flexibly with polynomial terms.10 Treatment weights were 
estimated with a logistic model, and censoring weights were estimated with a pooled logistic 
model, with time stratified into months since treatment initiation; these weights were 
stabilized by the marginal probability of treatment and censoring, respectively, and 
multiplied together to obtain weights for the marginal structural Cox proportional hazards 
model. The estimated treatment weights had a mean of 1.00 (range, 0.40–3.75). The 
estimated censoring weights for time to viral suppression had a mean of 1.00 (range, 0.12–
5.68). The estimated censoring weights for time to first regimen switch had a mean of 1.00 
(range, 0.65–2.72).
Finally, to account for differential monitoring for viral suppression by treatment group, we 
estimated viral monitoring weights for the probability of having a viral load measurement 
(or not) in a given month (with the probability taken to be that corresponding to the actual 
pattern of patient observation).11 The weights were estimated using pooled logistic 
regression and were conditional on all baseline covariates, the number of months since 
treatment initiation, and the number of months since the most recent viral load measurement, 
each modeled flexibly with polynomial terms. The weights were stabilized by the marginal 
probability of having a measured viral load (or not) in a given month. They were then 
multiplied cumulatively across time, by patient, and the final monitoring weights were 
multiplied by the treatment and censoring weights. The estimated monitoring weights for 
viral suppression had a mean of 0.99 (range, 0.02–9.31), and the final estimated weights had 
a mean of 0.98 (range, 0.04–14.00). The estimated monitoring weights for regimen switch 
had a mean of 1.02 (range, 0.06–43.48), and the final estimated weights had a mean of 1.02 
(range, 0.03–76.52).
The marginal structural Cox proportional hazards model fitted with the final weight 
estimates of the effect of PAM, as well as the effect of being seen as often as the average 
patient was seen for viral load monitoring at the clinic, with the assumption that there was 
no direct effect of viral load monitoring on the time to viral suppression (or, alternatively, on 
regimen switch). To relax this assumption, we fitted one more marginal structural Cox 
proportional hazards model that included an indicator for having had a visit within the prior 
three months and an interaction between the visit indicator and the treatment group.11 We 
report the hazard ratio (HR) and present adjusted Kaplan–Meier survival curves for the time 
to viral suppression. We report the median time on the initial ART regimen (i.e., the median 
time to ART regimen switch) for each treatment group, which was estimated from adjusted 
Kaplan–Meier survival curves for the time to switch.
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Initial regimen selection by antiretroviral drug class was descriptively examined by period of 
clinic entry and by PAM referral category. Trends in referral for PAM were examined by 
year of clinic entry. Propensity to refer for PAM according to clinician category (physician 
versus midlevel practitioner) was examined using logistic regression.




A total of 1758 treatment-naive patients were identified, of whom 383 were excluded from 
the analyses due to an undocumented (n = 379) or undetectable (n = 4) pretreatment viral 
load. An additional 120 patients were excluded due to an undocumented viral load after 
initiation of ART, leaving 1255 patients evaluable for viral suppression, 819 (65%) of whom 
received PAM services. Table 1 summarizes the characteristics of evaluable patients by 
study group. On average, PAM patients had somewhat more advanced HIV disease than 
non-PAM patients, as reflected in the former group's slightly higher pretreatment viral 
plasma load (mean, 4.9 log10 copies/mm3 versus 4.7 log10 copies/mm3) and lower CD4+ 
cell count (mean, 275 cells/mm3 versus 380/mm3). In addition, PAM patients were more 
likely to be coinfected with hepatitis B or C and to have acquired HIV infection through 
injection drug use. On average, PAM patients had more frequent viral load monitoring than 
non-PAM patients during the first six months of treatment but not during the second six 
months. Over the study period, data on 45 patients (4%) were censored because the patients 
were lost to follow-up. Censoring before viral suppression was more common among non-
PAM patients (n = 30, 7%) than among PAM patients (n = 15, 2%). Three hundred twenty-
four patients (26%) were censored before the end of follow-up for regimen switching. 
Censoring prior to regimen switching was more common among non-PAM patients (n = 
127, 29%) than among PAM patients (n = 197, 24%).
Primary endpoint
Figure 1 graphically depicts unadjusted and adjusted Kaplan–Meier estimates of the time to 
an undetectable HIV viral load (≤400 copies/mm3) by study group. In a Cox model fitted 
using inverse probability-of-treatment and censoring weights but not adjusted for differential 
monitoring frequency between the two groups, the PAM group achieved viral suppression 
1.41 times faster than the non-PAM group (95% confidence interval [CI], 1.22–1.63; p < 
0.0001). After adjusting for viral load monitoring, the adjusted HR for the joint effect of 
PAM and a standard visit schedule (i.e., a schedule consistent with the average visit 
frequency for the clinic) was 1.37 (95% CI, 1.18–1.59). The interaction between the PAM 
group and the indicator of having had a visit in the prior three months (a marker of 
monitoring frequency) was not significant (p = 0.88).
Secondary endpoints
Time to first regimen change—After adjusting for confounding, censoring, and 
differential monitoring frequency, the median durations of the first regimen were 100 and 44 
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months for the PAM and non-PAM groups, respectively. The cumulative rates of regimen 
change for the two groups did not diverge until around the fourth year after ART initiation. 
The differences in the rate of switch were not statistically significant in the marginal 
structural Cox proportional hazards model that adjusted for confounding of the treatment–
outcome relationship, censoring, and differential follow-up patterns between the groups 
(adjusted HR, 0.98; 95% CI, 0.74–1.30).
Changes in prescribing patterns—Table 2 summarizes the distribution of drug classes 
used in the initial antiretroviral regimens by study group and period of entry into treatment. 
Early in the study period and up to 2008, the majority of regimens initiated in the PAM 
group were protease inhibitor (PI) based; in the non-PAM group, nonnucleoside reverse 
transcriptase inhibitor (NNRTI)–based regimens were preferred until 2005. From 2009 
through 2013, prescribing patterns in the PAM and non-PAM groups were similar.
Table 3 shows rates of patient referral for PAM by year of clinic entry. From 1999 through 
2006, referrals for PAM averaged 69%. During the period 2007–11, there was a downward 
trend in referrals for PAM for initiation of ART in treatment-naive patients. During the final 
years of the study period (2012–13), the referral rate again increased. Midlevel practitioners 
were twice as likely as physicians to refer patients for PAM (odds ratio, 2.24; 95% CI, 1.72–
2.92). However, the effect of PAM was not modified by clinician category.
Discussion
In both the unadjusted and the adjusted analyses, patients with pharmacist-assisted ART 
management achieved more rapid viral suppression than patients managed without such 
assistance. Our results validated pharmacist activities (within the scope of a physician–
pharmacist collaborative practice protocol) to help optimize patient outcomes and provide an 
example of successful long-term use of a recently described model of care.12 Particularly in 
the context of the concept of “treatment as prevention” of further HIV transmission, 
achieving viral suppression earlier may have clinically important implications.
When differences in baseline characteristics were accounted for, we found that patients 
referred for PAM for ART initiation typically achieved viral suppression more rapidly than 
patients not receiving PAM services. PAM also was associated with more frequent 
monitoring of the HIV viral load during the first six months of ART, suggesting more 
frequent patient follow-up. This may be a component of PAM that is an important mediator 
of improved clinical outcomes. One potential explanation for the observed difference 
between the PAM and control groups with regard to viral suppression is that the PAM 
intervention resulted in patients receiving more frequent follow-up and provided more 
opportunities for education, support, and coaching regarding the importance of adherence, 
treatment goals, and management of adverse effects. While more frequent monitoring of 
viral load was observed in the PAM group, our results showed that the effect of PAM on 
viral suppression remained after accounting for different monitoring patterns, suggesting 
that the effect of PAM was not entirely explained by monitoring frequency. With regard to 
the longer durability of initial regimens among PAM patients in the adjusted analysis, we 
speculate that several factors may have contributed to this finding: initial selection of more 
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potent or better-tolerated regimens, more effective management of adverse effects and 
toxicities through more frequent monitoring, and more intensive adherence counseling than 
was available for the control patients.
Another objective of the study was to describe changes in prescribing patterns in the PAM 
and non-PAM groups. Changes in prescribing patterns over the study period in both the 
PAM and control groups were consistent with the availability of new antiretroviral agents 
over time. With the introduction of the first once-daily single-tablet regimen (tenofovir, 
emtricitabine, and efavirenz in a combined tablet form) in 2006, we observed an increase in 
the prescribing of NNRTI-based regimens relative to PI-based regimens. The most notable 
differences in prescribing patterns between the PAM and control groups occurred earlier in 
the study, during the period 1999–2008, when PAM patients were prescribed PI-based 
regimens more frequently than control patients.
A potential explanation for that difference in prescribing patterns is that, until 2006, baseline 
genotype tests were not routinely ordered prior to initiating treatment in treatment-naive 
patients; in the absence of baseline data on genetic resistance to HIV-1, patients with more 
advanced disease were typically initiated on PI-based regimens because of the higher HIV-1 
resistance thresholds such regimens offer relative to NNRTI-based regimens. When 
assessment of baseline resistance became the standard of care for treatment-naive patients, a 
shift toward NNRTI-based regimens and away from PI-based regimens was observed. 
Another possible explanation for the observed preference for PI-based regimens in the PAM 
group during the early years of the study period may pertain to clinician estimation of 
patient medication adherence. In a study of predictors of early ART adherence conducted in 
the same clinic involved in our study and published in 2002, pharmacists were found to 
predict ART adherence more accurately than other providers.13 For patients who required 
ART around that time but were deemed to be at risk for suboptimal adherence, PI-based 
regimens likely would have been preferred for their ability to foster a higher genetic barrier 
to resistance than that produced by NNRTI-based regimens and, thus, better accommodate 
imperfect adherence. Although unboosted PI regimens required more frequent dosing 
relative to NNRTI regimens, in the early 2000s clinical data indicating that ritonavir-boosted 
PI regimens could allow less frequent dosing and were associated with a lack of protease 
resistance at first viral failure were emerging.14 Guidelines published at the time also 
recognized the difficulty of designing effective regimens after viral failure on the first 
regimen and mentioned the preference of some experts for ritonavir-boosted PI regimens.15
Lastly, we investigated changes over time in the proportion of patients referred for PAM. 
Initially during the study period, approximately 60% of treatment-naive patients were 
referred for PAM for initiation of ART. With the availability of relatively less complex and 
better-tolerated regimens approved for treatment-naive patients, there may have been a sense 
among some providers that initiating ART did not require the extensive counseling or 
education required with traditional, more complex regimens. Although regimen 
simplification and a reduced pill burden help improve adherence, other predictors of 
adherence, such as health beliefs, also have a significant impact on adherence and the 
ultimate success of viral suppression. Even after controlling for the year of entry into 
treatment, the PAM group had accelerated viral suppression relative to the control group, 
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indicating a benefit of PAM with regard to achieving HIV treatment goals despite the 
availability of once-daily, one-tablet regimens.
There were several limitations to our study. First, the quality of the data depended on the 
accuracy and consistency of documentation in the EHR. There may have been some 
misclassification of PCP types resulting from investigator reliance on documented visit dates 
closest to ART initiation for provider classification purposes. Also, dates of ART initiation 
and regimen change were those recorded in the EHR and may not have corresponded to 
actual initiation and change dates. Second, the results of our study reflect experience in a 
treatment-naive population. It is likely that in a treatment-experienced population, the PAM 
group would have performed even better because of the expertise of the PAM clinicians in 
complex drug interactions, resistance, and adherence counseling. Third, the operational 
definition of the PAM group (i.e., it included any patient who was referred to the 
pharmacists and had a documented visit up to 365 days prior to ART initiation) was 
somewhat arbitrary, and a sensitivity analysis of the pretreatment PAM initiation window 
was not conducted. Because variations in the components and intensity of the PAM 
intervention were not explored, the transferability (external validity) of the intervention may 
be difficult to assess. Fourth, our definition of PAM did not account for the possibility of 
undocumented consultations between clinic pharmacists and providers prior to treatment 
initiation (this “curbside consulting” often happens in practice and may have an impact on 
treatment outcomes); the occurrence of informal pharmacist consultations would have 
tended to attenuate differences in evaluated outcomes between the two study groups. Fifth, 
although we attempted to use inverse probability weighting to control for confounding due 
to nonrandomized PAM assignment and selection bias due to differential viral load 
ascertainment frequency and differential data censoring, our inferences were subject to 
residual confounding and selection bias from unmeasured sources. Lastly, our analysis did 
not identify the specific elements of the PAM intervention (e.g., patient education, adherence 
counseling, toxicity recognition and management, regimen selection, monitoring plans) 
responsible for earlier viral suppression. Further investigation of these variables may provide 
more insight into mediating and moderating factors contributing to the observed differences 
in viral suppression between the PAM and control groups.
The study had two notable strengths: There was very minimal subject dropout prior to viral 
suppression, which decreased the likelihood of selection bias due to differential follow-up, 
and we accounted for different viral load monitoring frequencies in the PAM and control 
groups, which allowed us to separate the effect of the PAM program on the time to viral 
suppression from the effect of earlier detection of viral suppression.
Conclusion
In treatment-naive patients, suppression of HIV viral load occurred earlier when pharmacists 
assisted with initiating ART than when ART was initiated without that assistance.
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Unadjusted (left) and adjusted (right) Kaplan–Meier curves of the estimated time to 
undetectable HIV viral load (≤400 RNA copies/mm3) in patients for whom initiation of 
antiretroviral therapy (ART) occurred with pharmacist assistance (solid line, n = 819) or 
without such assistance (broken line, n = 436).
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Table 1
Characteristics of Patients Receiving and Not Receiving Pharmacist-Assisted Management (PAM) of 
Antiretroviral Therapy
a
Characteristic PAM (n = 819) No PAM (n = 436)
p 
b
Median (IQR) age at ART initiation, yr 37.7 (31.7-44.8) 35.3 (27.9-44.0) 0.0001
Sex, no. (%) 0.858
    Male 728 (89) 389 (89)
    Female 91 (11) 47 (11)
Median (IQR) baseline HIV viral load, log10 copies/mm3 4.9 (4.5-5.4) 4.7 (4.1-5.3) <0.00001
Median (IQR) CD4+ cell count, cells/mm3 234 (68-419) 371 (147-539) <0.00001
Presence of HIV risk factors, no. (%) 0.056
    MSM, not IDU 512 (63) 288 (66)
    IDU 243 (30) 104 (24)
    Other 64 (8) 44 (10)
Result of first test for HBsAg, no. (%) 0.952
    Negative 726 (89) 389 (89)
    Positive 40 (5) 20 (5)
    Result missing 53 (6) 27 (6)
Result of first test for HCV Ab, no. (%) 0.034
    Negative 707 (86) 393 (90)
    Positive 93 (11) 30 (7)
    Result missing 19 (2) 13 (3)
Race or ethnicity, no. (%) 0.038
    White 341 (42) 215 (49)
    Hispanic 304 (37) 146 (33)
    Black 117 (14) 56 (13)
    Other 57 (7) 19 (4)
Primary care provider, no. (%) <0.00001
    Physician 395 (48) 244 (56)
    Midlevel practitioner 399 (49) 110 (25)
    Not recorded 25 (3) 82 (19)
Median (IQR) no. viral load measurements
    During months 0-6 3 (2-4) 2 (1-3) <0.00001
    During months 7-12 1 (0-2) 1 (0-2) 0.2695
a
IQR = interquartile range, ART = antiretroviral therapy, HIV = human immunodeficiency virus, MSM = men having sex with men, IDU = 
injection drug use, HBsAg = hepatitis B surface antigen, HCV Ab = hepatitis C virus antibody.
b
Comparisons conducted with the Wilcoxon rank-sum test for medians and the chi-square test for categorical results.
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Table 2
Drug Classes in Initial Regimens for Patients Receiving and Not Receiving Pharmacist-Assisted Management 
(PAM) of Antiretroviral Therapy in HIV Clinic (n = 1255)
a
Proportion of Initial Regimens Containing Drug in Indicated Class
Drug Class Clinic Entry, 1999-2001 Clinic Entry, 2002-04 Clinical Entry, 2005-08 Clinic Entry, 2009-13
Patients With PAM
    NNRTI 0.44 0.29 0.42 0.52
    PI 0.52 0.63 0.57 0.42
    INSTI 0 0 0.01 0.09
Patients Without PAM
    NNRTI 0.51 0.54 0.52 0.47
    PI 0.46 0.36 0.43 0.50
    INSTI 0.01 0 0.03 0.04
a
HIV = human immunodeficiency virus, NNRTI = nonnucleoside reverse transcriptase inhibitor, PI = protease inhibitor, INSTI = integrase strand 
transfer inhibitor.
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Table 3
Referrals for Pharmacist-Assisted Management (PAM) of Antiretroviral Therapy



















p = 0.006 for comparison of fractions receiving and not receiving PAM over time (Pearson χ2 [14 d.f.] = 31.008).
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